Recent developments of thromboxane modulators

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 11, 2001, Pages 1663-1675

  Dogne J M ^a   De Leval, X ^a   Delarge, J ^a   Masereel, B ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Thromboxane; Thromboxane antagonists; Thromboxane synthase inhibitors; TP receptors; TXA2

Indexed keywords

11 [2 (5,6 DIMETHYL 1 BENZIMIDAZOLYL)ETHYLIDENE] 6,11 DIHYDRODIBENZ[B,E]OXEPINE 2 CARBOXYLIC ACID; 3 [4 (3 PYRIDYLMETHYL)PHENYL]METHACRYLIC ACID; 4,5 DIHYDRO 2 (1H IMIDAZOL 1 YLMETHYL) 6 BENZO[B]THIOPHENECARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ACETYLSALICYLIC ACID; DALTROBAN; DAZMEGREL; DAZOXIBEN; DOMITROBAN; FUREGRELATE; ICOSANOID; IFETROBAN; IMIDAZOLE; ISBOGREL; LINOTROBAN; OZAGREL; PICOTAMIDE; PIRMAGREL; PROSTAGLANDIN SYNTHASE; RAMATROBAN; RIDOGREL; SERATRODAST; SULOTROBAN; TERBOGREL; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPIPROST;

ASTHMA; CELL STIMULATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG SYNTHESIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MALE; MEDICAL LITERATURE; METASTASIS; PATENT; PATHOPHYSIOLOGY; PREECLAMPSIA; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE CONTRACTILITY; THROMBOCYTE AGGREGATION; TUMOR GROWTH;

EID: 0034752474     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.11.1663     Document Type: Review

References (86)

1. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
2. 2
3. Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures
4. 2: Biosynthesis and effects on platelets
5. 2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis
6. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
7. 2 production
8. 2 on some isolated smooth muscle preparations
9. Studies on the characterisation of prostanoid receptors: A proposed classification
10. 2 receptors in platelets and blood vessels: Evidence for different receptors
11. 2 receptor
12. 2 receptor
13. Increased thromboxane biosynthesis in a human preparation of platelet activation: Biochemical and functional consequences of selective inhibition of thromboxane synthase
14. Platelet activation in unstable coronary disease
15. Biochemical evidence of platelet activation in patients with persistent unstable angina
16. Preeclampsia: An imbalance in placental prostacyclin and thromboxane production
17. 2 production in allergen-induced immediate and late asthmatic responses. Its possible role in inducing the late response
18. 2 production in patients with systemic lupus erythematosus
19. 2 by coronary arteries after thrombolysis
20. New trends in thromboxane and prostacyclin modulators
21. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids
22. Spectral studies on structure-activity relationships of thromboxane synthase inhibitors
23. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets
24. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity
25. 2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046)
26. Pharmacodkinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers
27. Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers
28. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models
29. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage
30. Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction
31. Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery
32. 2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia
33. 2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: A preliminary report
34. OKY-1581, a potential selective thromboxane synthetase inhibitor
35. 2 synthase activity by sodium 5-(3′-pyridinylmethyl)benzofuran-2-carboxylate
36. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers
37. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death
38. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets
39. 2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug
40. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man
41. Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma
42. Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma
43. 2 receptor antagonist in asthmatic patients?
44. 7-Oxabicycloheptane analogs: Modulators of the arachidonate cascade
45. 2 (TP) receptors in human platelet membranes
46. Protective actions of a thromboxane receptor antagonist, SQ 29548 on the ischemic myocardium: Morphologic and hemodynamic effects
47. 2 antagonists: Aza omega-chain analogues
48. 2/prostaglandin endoperoxide receptor antagonist
49. Synthesis and in vitro activity of various derivatives of a novel thromboxane receptor antagonist, (+/-)-(5Z)-7-[3-endo-[(phenylsulfonyl)-amino]bicyclo[2.2.1] hept-2-exoyl]heptenoic acid
50. 2 receptor antagonists. I. Synthesis and pharmacological activity of 7-oxabicyclo-[2.2.1]heptane derivatives with the benzenesulfonylamino group
51. 2 receptor antagonist, S-1452, and its effect on platelet aggregation in healthy volunteers
52. 2 (TXA2/PGH2) partial agonist, (+)5(Z)-7- [3-endophenylsulfonylamino [2.2.1]- bicyclohept-2-exo-yl]- heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function
53. 2 inhibitors on allergic pulmonary inflammation in mice
54. Effect of thromboxane A(2) (TXA(2)) synthase inhibitor and TXA(2) receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs
55. Role of chemical mediators in airway hyperresponsiveness in an asthmatic model
56. A specific thromboxane receptor blocking drug, AH23848, reduces platelet deposition on vascular grafts in man
57. 2-receptor blocker
58. 2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191
59. 2- and allergen-induced bronchoconstriction
60. 2 and sphingosine
61. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding
62. BM 13.177 selectively inhibits endoperoxide analogue induced vascular contractions
63. 2 receptor antagonists in smooth muscle cells
64. 2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions
65. Evidence for partial agonist properties of daltroban (BM 13,505) at TP receptors in the anaesthetized open-chest rat
66. 2 antagonistic activity of indane derivatives
67. A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time
68. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats
69. 2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl) sulfonyl]amino]methyl] cyclopentyl] methyl]benzeneacetate
70. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenyl -sulfonamido)- 1,2,3,4-tetrahydro- 9-carbazolepropanoic acid
71. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3- (4-fluorophenylsulfonamido)- 1,2,3,4- tetrahydro-9- carbazolepropanoic acid
72. Action of the novel selective thromboxane antagonist (3R)-3- (4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid on vascular smooth muscle preparations
73. 2 antagonist, reduces bronchial hyperresponsiveness in asthmatics
74. 2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in allergic rhinitis
75. Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: Potentiation of antiplatelet effects of aspirin
76. 2 receptor
77. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6, 11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate
78. 2/prostaglandin endoperoxide receptor in platelets and blood vessels
79. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism
80. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction
81. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic Type IIa subjects
82. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat
83. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors
84. Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: A 1-year observational study
85. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: A retrospective analysis of the ADEP study
86. Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: A 6-year follow-up study